Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | HTT | P42858 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.51 |
| ▸ | TUBB | P07437 | 1/20 | 0.51 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.51 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.51 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.51 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.51 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.51 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.51 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.51 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.51 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.51 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.51 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.51 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.51 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16539464 | 0.93 | SMN1; SMN2 (0.54) | SMN1; SMN2HTTLMNATUBB4ATUBB | |
| SCHEMBL16538936 | 0.91 | LMNA (0.58) | SMN1; SMN2HTTLMNATUBB4ATUBB | |
| SCHEMBL16539397 | 0.89 | SMN1; SMN2 (0.53) | SMN1; SMN2HTTLMNAMAPTKMT2A | |
| SCHEMBL16539600 | 0.89 | SMN1; SMN2 (0.50) | SMN1; SMN2HTTLMNAMAPTKMT2A | |
| SCHEMBL16539566 | 0.86 | NPC1 (0.56) | SMN1; SMN2HTTLMNAMAPTKMT2A | |
| SCHEMBL16539559 | 0.86 | SMN1; SMN2 (0.65) | SMN1; SMN2HTTLMNAMAPTKMT2A | |
| SCHEMBL16539686 | 0.85 | POLB (0.55) | SMN1; SMN2HTTLMNAKMT2AMEN1 | |
| SCHEMBL16538970 | 0.85 | MEN1 (0.63) | SMN1; SMN2HTTLMNAMAPTKMT2A | |
| SCHEMBL16539321 | 0.84 | KMT2A (0.54) | SMN1; SMN2HTTLMNAMAPTKMT2A | |
| SCHEMBL16539015 | 0.84 | STAT3 (0.51) | SMN1; SMN2HTTLMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3038612-B1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-07-29 | — | — | EP | claimed |
| EP-3038612-B1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-07-29 | — | — | EP | disclosed |
| US-10351511-B2 | Cyclic vinylogous amides as bromodomain inhibitors | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180105485-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-04-19 | — | — | US | disclosed |
| US-9884806-B2 | Cyclic vinylogous amides as bromodomain inhibitors | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160200666-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2016-07-14 | — | — | US | disclosed |
| EP-3038612-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | Icahn School of Medicine at Mount Sinai (US) | 2016-07-06 | — | — | EP | disclosed |
| WO-2015031824-A9 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2015031824-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2015-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200666-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | BRD1, BRD4, BRDT | SMN1; SMN2 4314/4885HTT 3022/4885LMNA 3273/4885 |
| US-10351511-B2 | Cyclic vinylogous amides as bromodomain inhibitors | BRD1, BRD4, BRDT | SMN1; SMN2 4314/4885HTT 3022/4885LMNA 3273/4885 |
| US-20180105485-A1 | CYCLIC VINYLOGOUS AMIDES AS BROMODOMAIN INHIBITORS | BRD1, BRD4, BRDT | SMN1; SMN2 4314/4885HTT 3022/4885LMNA 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.